Anuh Pharma Ltd: ₹710 Cr Sales, Macrolides, and a Side of Dividend Payout

1. At a Glance

Anuh Pharma (APL) has been cooking APIs since 1960, making antibiotics, anti-TB drugs, and a buffet of bulk molecules. They’re the desi “antibiotic ka theka”—largest producer of erythromycin salts in India and top 5 globally. FY25 revenue stood at ₹710 Cr, profit at ₹46 Cr, margins ~9%. The company is debt-light, dividend-friendly, but facing margin pressures. Stock trades at ₹88.9 (mcap ~₹886 Cr), ~19× earnings—cheaper than big pharma cousins but still not a bargain-bin pick.

2. Introduction

Think of Anuh Pharma as that steady uncle in the pharma family—not a flashy billionaire like Sun Pharma, not a research genius like Divi’s, but a dependable bulk supplier with global reach.

The SK Group-backed company thrives in APIs, especially macrolides (azithromycin, roxithromycin) and anti-TB drugs (pyrazinamide, isoniazid). With exports forming 45% of revenue, their client list spans 57 countries. On paper, it’s a “hidden gem.”

But here’s the drama: profits fell 20% last year even though sales grew. Why? Rising input costs, regulatory compliance overheads, and Chinese pricing pressure. In APIs, life is tough—one quarter you’re “largest erythromycin producer,” the next you’re negotiating margins thinner than papad.

Question for you: would you back a company whose claim to fame is “we sell bulk drugs, but don’t expect bulk profits”?

3. Business Model (WTF Do They Even Do?)

Anuh makes APIs/bulk drugs and sells them worldwide. No brands, no sexy marketing—just molecules in kilos and tonnes.

• Core products: Erythromycin, azithromycin, pyrazinamide, chloramphenicol.
• New launches: Vildagliptin, Moxifloxacin, Allopurinol, Acebrophylline.
• Pipeline: Dapagliflozin, Empagliflozin, Ticagrelor—diabetes and cardiac APIs, because lifestyle diseases are India’s biggest export after software engineers.
• Customers: 350+ across 57 countries, including regulated markets like Europe (via CEP, WHO GMP, EDQM approvals).

The trick? No blockbuster drugs, just steady demand molecules. Think of them as the wholesale mandi of APIs.

4. Financials Overview

Commentary: Topline steady, bottom line slightly down. Margins